These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27492892)

  • 1. Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
    Hellner K; Miranda F; Fotso Chedom D; Herrero-Gonzalez S; Hayden DM; Tearle R; Artibani M; Carrami EM; Williams R; Gaitskell K; Elorbany S; Xu R; Laios A; Buiga P; Ahmed K; Dhar S; Zhang RY; Campo L; Myers KA; Lozano M; Ruiz-Miró M; Gatius S; Mota A; Moreno-Bueno G; Matias-Guiu X; Benítez J; Witty L; McVean G; Leedham S; Tomlinson I; Drmanac R; Cazier JB; Klein R; Dunne K; Bast RC; Kennedy SH; Hassan B; Lise S; Garcia MJ; Peters BA; Yau C; Sauka-Spengler T; Ahmed AA
    EBioMedicine; 2016 Aug; 10():137-49. PubMed ID: 27492892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-neoplastic Fallopian Tube Epithelium Carrying Gene Mutations of a Novel SOX2 Repressor Region is Soil of High-grade Serous Ovarian Cancer.
    Hirohashi Y; Torigoe T
    EBioMedicine; 2016 Aug; 10():17-8. PubMed ID: 27423191
    [No Abstract]   [Full Text] [Related]  

  • 3. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
    George SH; Milea A; Shaw PA
    Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
    Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
    Press JZ; Wurz K; Norquist BM; Lee MK; Pennil C; Garcia R; Welcsh P; Goff BA; Swisher EM
    Neoplasia; 2010 Dec; 12(12):993-1002. PubMed ID: 21170264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells.
    Hollingsworth J; Lau A; Tone A; Kollara A; Allen L; Colgan TJ; Dube V; Rosen B; Murphy KJ; Greenblatt EM; Feigenberg T; Virtanen C; Brown TJ
    Neoplasia; 2018 Jul; 20(7):697-709. PubMed ID: 29852322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
    Carcangiu ML; Radice P; Manoukian S; Spatti G; Gobbo M; Pensotti V; Crucianelli R; Pasini B
    Int J Gynecol Pathol; 2004 Jan; 23(1):35-40. PubMed ID: 14668548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
    Veskimäe K; Staff S; Tabaro F; Nykter M; Isola J; Mäenpää J
    Genes Chromosomes Cancer; 2015 May; 54(5):276-87. PubMed ID: 25706666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
    Yates MS; Meyer LA; Deavers MT; Daniels MS; Keeler ER; Mok SC; Gershenson DM; Lu KH
    Cancer Prev Res (Phila); 2011 Mar; 4(3):463-70. PubMed ID: 21278312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of βV-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia.
    Mathew D; Wang Y; Van Arsdale A; Horwitz SB; McDaid H
    Int J Gynecol Cancer; 2018 Feb; 28(2):363-370. PubMed ID: 29298171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.
    Yucer N; Ahdoot R; Workman MJ; Laperle AH; Recouvreux MS; Kurowski K; Naboulsi DJ; Liang V; Qu Y; Plummer JT; Gayther SA; Orsulic S; Karlan BY; Svendsen CN
    Cell Rep; 2021 Dec; 37(13):110146. PubMed ID: 34965417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.
    Tone AA; Begley H; Sharma M; Murphy J; Rosen B; Brown TJ; Shaw PA
    Clin Cancer Res; 2008 Jul; 14(13):4067-78. PubMed ID: 18593983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    Cass I; Walts AE; Barbuto D; Lester J; Karlan B
    Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
    J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
    Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
    JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.
    Smith NL; Welcsh P; Press JZ; Agnew KJ; Garcia R; Swisher EM
    Genes Chromosomes Cancer; 2012 Nov; 51(11):1054-62. PubMed ID: 22887716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.